Industrial-scale, genomics-based drug design and discovery.
The demands on drug discovery organizations have increased dramatically in recent years, partly because of the need to identify novel targets that are both relevant to disease and chemically tractable. This is leading to an industrial approach to traditional biology and chemistry, inspired in part by the revolution in genomics. The purpose of this article is to highlight the flow of investigation from gene sequence of potential therapeutic targets, through mRNA and protein expression, to protein structure and drug design. To deal with this scale of activity, many commercial and public organizations have been established and some of the key players will be listed in this article.
Dean
P M
PM
De Novo Pharmaceuticals Ltd, St Andrew's House, 59 St Andrew's Street, CB2 3DD., Cambridge, UK. philip.dean@denovopharma.com
Zanders
E D
ED
Bailey
D S
DS
D015195:Drug Design; D015870:Gene Expression; D016678:Genome; D020411:Oligonucleotide Array Sequence Analysis; D010597:Pharmacogenetics; D011506:Proteins / Q000235:genetics; D020543:Proteome; D012333:RNA, Messenger / Q000235:genetics
D011506:Proteins; D020543:Proteome; D012333:RNA, Messenger